drugset
drugset / Trial / NCT00304590

Study of XL999 in Patients With Multiple Myeloma

NCT00304590 ↗

Phase 2 Terminated 4 enrolled Symphony Evolution, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This clinical study is being conducted at multiple sites to determine the activity, safety, and tolerability of XL999 when given weekly to patients with relapsed or refractory multiple myeloma. XL999 is a small molecule inhibitor of cellular factors including VEGFR, PDGFR, and FGFR that may be involved in multiple myeloma.

Timeline

Start
2006-02
Primary completion
2006-12
Completion
2007-05

Outcome

Outcome not reported

Stopped: “Study was terminated due to cardiac toxicities in the subjects”

Drugs

EvaluationDrugModalityDoseRoute
Subject XL999 Small molecule 2.4 mg/kg —

Indications

plasma cell myeloma